Clinical Trials Logo
  1. Home
  2. Coronary Artery Bypass Grafting
  3. NCT02430012

Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Secondary Prevention — MISSION-1  

Coronary Artery Bypass Grafting Clinical Trial

Official title:
Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Secondary Prevention

Clinical Trial Summary

The investigators have identified underuse of secondary prevention medications at discharge of patients underwent coronary artery bypass grafting (CABG) in China. The aim of this study is to develop series of quality improvement strategies focusing on secondary prevention medications for patients underwent CABG, and to evaluate their effectiveness and safety via a hospital-level cluster randomized clinical trial. The investigators established a network of 60 hospitals which have participated into Chinese Cardiovascular Surgery Registry and submitted 50 or more CABG surgeries already. The participating sites will be divided into intervention and control groups in a 1:1 ratio. The intervention group will undertake intervention of quality improvement strategies, while the control group will maintain the routine practice pattern. All hospitals will consecutively enroll and submit data of CABG during the enrollment period, estimated for 6 months. The prescribing rates of angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), beta-blockers, statins and aspirins will be compared between 2 groups.

Clinical Trial Description

The investigators have identified underuse of secondary prevention medications at discharge of patients underwent coronary artery bypass grafting (CABG) in China. The aim of this study is to develop series of quality improvement strategies focusing on secondary prevention medications for patients underwent CABG, and to evaluate their effectiveness and safety via a hospital-level cluster randomized clinical trial. The investigators established a network of 60 hospitals which have participated into Chinese Cardiovascular Surgery Registry and submitted 50 or more CABG surgeries already. The participating sites will be divided into intervention and control groups in a 1:1 ratio. The intervention group will undertake intervention of quality improvement strategies, while the control group will maintain the routine practice pattern. All hospitals will consecutively enroll and submit data of CABG during the enrollment period of estimated 6 months. The prescription rates of ACEI, ARB, beta-blockers, statins and aspirins will be compared between 2 groups.

Before the enrollment period, the investigators have developed series of quality improvement strategies focusing on secondary prevention medications for patients underwent CABG, including training with guidelines of secondary preventions, determining improvement goals with participating sites, intervention tools (workflow posters and cards, checklists to inform the use of secondary prevention medications) and periodical quality feedback reports.

In the enrollment period, participating hospitals will be divided into intervention and control groups in a 1:1 ratio using minimization allocation.

The investigators will collect data on the prescription rates from central medical record abstraction, case report forms submitted by participating sites and checklists submitted by intervention groups. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02430012
Study type Interventional
Source China National Center for Cardiovascular Diseases
Contact
Status Completed
Phase N/A
Start date June 2015
Completion date September 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT01850082 - Randomized Endo-Vein Graft Prospective N/A
Not yet recruiting NCT04657835 - Assessment of Atrial Cardiomyopathy Using MRI as a Predictor of Cardiac Post-Operative Atrial Fibrillation After Cardiac Surgery. N/A
Completed NCT02889562 - Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Phase 2/Phase 3
Completed NCT01528514 - Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study N/A
Completed NCT01378221 - VItamin D Metabolism in SEnescent Cardiac Surgery Patients N/A
Completed NCT00848796 - Comparative Study of Two Brands of Heparin Already on the Market N/A
Not yet recruiting NCT05552586 - Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery N/A
Completed NCT00246740 - Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting Phase 2
Completed NCT00420667 - Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery N/A
Recruiting NCT04197700 - The PRESSURE CABG Cardiac Surgery Trial N/A
Not yet recruiting NCT05835167 - Complete Revascularization Via Inferior Part-sternotomy N/A
Not yet recruiting NCT06433960 - Radial Artery Assessment in Surgical Coronary Revascularisation
Not yet recruiting NCT06326996 - Thiamine Intervention and Coronary Artery Bypass Grafting N/A
Not yet recruiting NCT02732574 - Oscillating Positive Expiratory Pressure (OPEP) Therapy in High Risk Patients Following Cardiac Surgery N/A
Completed NCT00903604 - Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac Surgery Phase 2
Completed NCT01182688 - Prospective Review of Procalcitonin After Cardiac Surgery N/A
Completed NCT02737215 - Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Obstructive Sleep Apnea N/A
Recruiting NCT03209414 - Frailty Syndrome in Daily Practice of Interventional Cardiology Ward
Recruiting NCT05441358 - Assessment of Platelet Function in Patients Undergoing Open Heart Surgery